Do you want to read an article? Please log in or register.
A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study
Lancet Gastroenterol Hepatol
Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S
doi: 10.1016/S2468-1253(25)00017-2
RECOMMENDED
Inflammatory Bowel Disease
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
★ 3
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Lancet Gastroenterol Hepatol
Danese S, Allegretti JR, Schreiber S, Peyrin-Biroulet L, Jairath V, D'Haens G, Kierkuś J, Leong RW, Yarur AJ, Vincent MS, Banerjee A, Chandra DE, Peeva E, Neelakantan S, Hung KE, McBride JM, Bojic D, Lasch K, Schiffman C, Feagan BG
doi: 10.1016/S2468-1253(25)00129-3
Inflammatory Bowel Disease
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program
Inflamm Bowel Dis
Sands BE, Dubinsky MC, Kotze PG, Vermeire S, Panaccione R, Long MD, Woolcott JC, Wu J, McDonnell A, Goetsch M, Bananis E, Yarur AJ
doi: 10.1093/ibd/izaf036
Inflammatory Bowel Disease
Anti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype
J Crohns Colitis
Pertsinidou E, Salomon B, Bergemalm D, Salihovic S, Hedin CRH, Ling Lundström M, Keita ÅV, Magnusson MK, Eriksson C, Bengtson MB, Grännö O, Aabrekk TB, Movérare R, Rydell N, Ekoff H, Rönnelid J, BIO-IBD consortium, D'Amato M, Detlie TE, Huppertz-Hauss G, Opheim R, Ricanek P, Kristensen VA, Öhman L, Söderholm JD, Kruse R, Lindqvist CM, Carlson M, Repsilber D, Høivik ML, Halfvarson J
doi: 10.1093/ecco-jcc/jjaf062
Inflammatory Bowel Disease
Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis
J Crohns Colitis
D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S
doi: 10.1093/ecco-jcc/jjaf080
Inflammatory Bowel Disease
Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension Study
J Crohns Colitis
Loftus EV Jr, D'Haens G, Louis E, Regueiro M, Jairath V, Magro F, Nakase H, Dubcenco E, Lacerda AP, Ford S, Feng T, Duncan B, Fish I, Cunneen C, Anyanwu SI, Aponte F, Griffith J, Blumenstein I
doi: 10.1093/ecco-jcc/jjaf138
Inflammatory Bowel Disease
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study
Gastroenterology
Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D'Haens G
doi: 10.1053/j.gastro.2025.02.033
Inflammatory Bowel Disease
Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis
Adv Ther
Dignass A, Ainsworth C, Hartz S, Dunnewind N, Redondo I, Sapin C, Kroep S, Halfpenny N, Arcà E, Hoque S
doi: 10.1007/s12325-024-03003-8
Inflammatory Bowel Disease
Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint
J Crohns Colitis
Colombel JF, Wu J, Kobayashi T, Zhu B, Paulissen J, Dhanabal A, Jairath V, Siegel C, Siegmund B, Redondo I, Moses R, Magro F
doi: 10.1093/ecco-jcc/jjaf124